Dermavant Sciences, an Organon company
A Passion for Science and a Commitment to Dermatology
A Passion for Science and a Commitment to Dermatology
Dermavant Sciences, an Organon company
Founded in 2016, Dermavant Sciences is a specialty biopharmaceutical company with a strong focus on dermatologic diseases. The company's dedication to innovation is exemplified by its commitment to developing and commercializing novel first-in-class or best-in-class therapies that address unmet therapeutic needs. This commitment is further underscored by Marathon Fund and Novaquest Capital Management's $160.00M Private Equity Round investment in the company on 07 June 2021.
Dermavant Sciences' passion for science and patient-centric approach are at the core of its operations, driving the company's efforts to improve patients' lives through biomedical research. The company's acquisition of promising compounds and establishment of a robust dermatology R&D pipeline further underscore its commitment to advancing dermatologic treatment options.
With its headquarters in the United States, Dermavant Sciences, as a part of the Organon company, is well-positioned to make a significant impact in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Private Equity Round | $160.00M | 2 |
|
07 Jun 2021 |
No recent news or press coverage available for Dermavant Sciences, an Organon company.
We care about your data, and we'd love to use cookies make your experience better.
